Core Insights - The company reported a revenue of 165 million yuan for the first half of 2025, representing a year-on-year decline of 27.03% [1] - The net profit for the same period was 24.34 million yuan, showing a significant decrease of 68.24% compared to the previous year [1] Financial Performance - Revenue: 165 million yuan, down 27.03% year-on-year [1] - Net Profit: 24.34 million yuan, down 68.24% year-on-year [1]

Financial Performance - The company reported a significant increase in revenue for the first half of 2025, with total revenue reaching RMB 500 million, representing a 25% year-over-year growth[12]. - The company reported a revenue of CNY 164.62 million for the first half of the year, a decrease of 27.03% compared to the same period last year[20]. - The total profit for the period was CNY 27.83 million, down 67.14% year-on-year, while the net profit attributable to shareholders decreased by 68.24% to CNY 24.34 million[20]. - Basic and diluted earnings per share were both CNY 0.06, reflecting a decline of 68.42% compared to the previous year[19]. - The net cash flow from operating activities decreased by 48.70% to CNY 39.78 million, primarily due to reduced sales collections[20]. - The company achieved operating revenue of 164.62 million yuan, a decrease of 27.03% compared to the same period last year[47]. - Net profit attributable to the parent company was 24.34 million yuan, down 68.24% year-on-year[47]. - The company reported a net loss distribution to owners of 49,324,143.30, reflecting challenges in profitability[155]. Market Outlook and Strategy - The company provided a positive outlook for the second half of 2025, projecting a revenue growth of 20% to 30% based on current market trends and product demand[12]. - The company is expanding its market presence, targeting new regions in Southeast Asia, with plans to establish partnerships with local distributors by Q4 2025[12]. - The company is actively responding to industry challenges by optimizing product structure and enhancing operational efficiency[20]. - The company is focusing on integrating AI and big data to enhance product usability and accuracy in immunodiagnostics[44]. - The company is expanding its market presence by transitioning from single products to comprehensive laboratory solutions, improving efficiency for medical institutions[44]. Research and Development - Research and development efforts are focused on innovative diagnostic technologies, with an investment of RMB 50 million allocated for the development of next-generation testing kits[12]. - The company's R&D expenditure accounted for 21.68% of its operating revenue, an increase of 4.12 percentage points from the previous year[19]. - The company has developed 87 products in the LiCA® series, covering common clinical testing items in infectious diseases, tumor markers, thyroid hormones, reproductive endocrine hormones, cardiac markers, and inflammation[40]. - The company is actively developing clinical diagnostic tools for Alzheimer's disease and cancer, aiming for early detection and personalized treatment[48]. - The company has ongoing projects with a total expected investment of ¥50,000,000 for the LiCA® homogeneous immunoassay reagent development, with ¥1,499,040 invested in the current period[73]. Product Development and Innovation - New product launches included the LiCA® series, which has shown a 30% improvement in sensitivity compared to previous models, enhancing the company's competitive edge in the market[12]. - The company has established a proprietary chemiluminescence technology platform and developed the LiCA® series of diagnostic products[26]. - The LiCA® series products demonstrate superior performance with sensitivity rates of 96.39% and specificity rates of 99.95%, outperforming international leading brands[52]. - The LiCA® 800 instrument can achieve a maximum testing speed of 600 tests per hour, significantly surpassing international leading brands[40]. - The company has obtained 221 domestic medical device registration certificates and 338 authorized patents, including 142 invention patents, as of June 30, 2025[37]. Compliance and Governance - The company has no significant non-operating fund occupation by controlling shareholders or related parties, ensuring financial integrity[6]. - There are no violations of decision-making procedures regarding external guarantees, maintaining compliance with regulatory standards[6]. - The board of directors confirmed that all members attended the meeting, ensuring transparency and governance in decision-making processes[4]. - The report emphasizes the importance of risk management, detailing potential risks in the operational environment and strategies to mitigate them[3]. Shareholder and Equity Management - The company has not proposed any profit distribution or capital reserve transfer plans for the half-year period[92]. - The company has implemented a stock incentive plan, which was approved in December 2021, to motivate and retain key personnel[93]. - The company has approved the cancellation of 963,000 shares of unvested restricted stock due to performance criteria not being met for the second vesting period[95]. - The company has committed to ensuring that the public offering of shares does not involve any fraudulent issuance, with a buyback program initiated within five working days if conditions are not met[98]. - The company has a long-term commitment to fulfill its promises regarding profit distribution and shareholder returns post-listing[99]. Financial Position and Assets - The total assets at the end of the reporting period were CNY 1.77 billion, a decrease of 3.32% from the previous year[20]. - The net assets attributable to shareholders decreased by 1.76% to CNY 1.39 billion[20]. - The company's total current assets decreased to RMB 1,016,759,119.84 from RMB 1,067,681,904.23 in the previous period[134]. - The company's fixed assets as of June 30, 2025, were valued at RMB 441,702,666.38, a decrease from RMB 453,868,944.92 at the end of 2024[134]. - Total liabilities decreased by 8.60% to CNY 380.09 million, resulting in a debt-to-asset ratio of 21.46%[77].

证券代码：688468 证券简称：科美诊断 公告编号：2025-017 科美诊断技术股份有限公司 2025 年半年度募集资金存放与使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 | 项目 | 金额 | | --- | --- | | 募集资金总额 | 293,150,000.00 | | 减：发行有关费用 | 44,593,051.99 | | 募集资金净额 | 248,556,948.01 | | 减：募集资金累计使用金额（包括置换先期投入金额） | 256,420,885.27 | | 其中：新建体外诊断试剂生产基地项目 | | | 123,143,353.57 | | --- | --- | --- | --- | | LiCA®试剂与配套仪器研发（实验室）项目 | | | 89,094,974.74 | | LiCA®试剂与关键生物原料研发项目 | | | 44,182,556.96 | | 减：支付发行费用的税金金额 | | | 2,128,301.88 | | 减：期末 ...

为深入贯彻党的二十大和中央金融工作会议精神，落实国务院《关于进一 步提高上市公司质量的意见》要求，积极响应上海证券交易所《关于开展沪市 公司"提质增效重回报"专项行动的倡议》，推动公司高质量发展和投资价值 提升，保护投资者尤其是中小投资者合法权益，科美诊断技术股份有限公司（ 以下简称"公司"）结合发展战略和实际经营情况制定了2025年度"提质增效 重回报"行动方案（以下简称"《行动方案》"），具体内容详见公司2025年 4月29日披露的《2024年度"提质增效重回报"行动方案的评估报告暨2025年 度"提质增效重回报"专项行动方案》。 2025年上半年，公司切实履行并持续评估《行动方案》的具体举措，现将 《行动方案》在报告期内的实施和效果评估情况报告如下： 一、聚焦主业，提升经营质效 2025年上半年，面对复杂多变的市场环境，公司始终坚持贯彻"以创新服 务人类健康"的经营理念，稳步推进公司长期战略。在医疗行业持续推进高质 量发展的大背景下，围绕技术和产品优势，以临床需求为导向，多种方式相结 合促进公司战略规划的顺利实施；以创新为第一动力，形成具有市场竞争力的 优质产能，着力为发展"新质生产力"蓄势赋能，推动技 ...

Group 1 - The core viewpoint of the news highlights the financial performance and trading activity of Kemei Diagnostics, indicating a decline in revenue and net profit for the first quarter of 2025 compared to the previous year [2] - As of August 26, Kemei Diagnostics experienced a financing net buy of -2.23 million yuan, with a total financing and securities balance of 206 million yuan, which is 5.86% of its market capitalization [1] - The company has a significant reliance on its LiCA series products, which account for 92.04% of its main business revenue [1] Group 2 - As of March 31, the number of shareholders for Kemei Diagnostics increased by 14.69% to 11,000, while the average circulating shares per person decreased by 12.81% to 36,384 shares [2] - For the first quarter of 2025, Kemei Diagnostics reported an operating income of 81.30 million yuan, a year-on-year decrease of 27.01%, and a net profit attributable to shareholders of 14.54 million yuan, down 62.12% year-on-year [2] - The company has distributed a total of 306 million yuan in dividends since its A-share listing, with 238 million yuan distributed over the past three years [3]

Core Points - The company, Kemei Diagnostics Technology Co., Ltd. (688468), is holding its first extraordinary shareholders' meeting in 2025 to ensure the rights of all shareholders and maintain order during the meeting [1][2] - The meeting will include discussions and voting on several key proposals, including amendments to the company's articles of association and the election of board members [6][10][14] Meeting Procedures - Shareholders and their representatives must register 30 minutes before the meeting and present necessary identification documents to participate [1][2] - The meeting will follow a structured agenda, including the election of monitors and the review of various proposals [6][10] - Voting will be conducted both on-site and online, with specific time frames for each method [5][6] Proposals Overview - Proposal 1: Amendment of the company's articles of association to enhance governance structure [8][10] - Proposal 2: Revision of several governance systems to align with legal requirements and improve operational standards [10][12] - Proposal 3: Appointment of Rongcheng Accounting Firm as the auditor for the 2025 fiscal year [12] - Proposal 4: Election of new board members, with a total of nine members proposed for the third board [14][15] - Proposal 5: Election of independent directors, with new candidates nominated due to the expiration of terms for current independent directors [17]

证券代码：688468 证券简称：科美诊断 科美诊断技术股份有限公司 2025年第一次临时股东会会议资料 二零二五年九月 三、 股东及股东代理人参加股东会依法享有发言权、质询权、表决权等 权利。股东及股东代理人参加股东会应认真履行其法定义务，不得侵犯公司和其 他股东及股东代理人的合法权益，不得扰乱股东会的正常秩序。 四、 股东及股东代理人要求在股东会现场会议上发言的，应于股东会召 开前一天向大会会务组进行登记。大会主持人根据会务组提供的名单和顺序安排 发言。 | 2025 年第一次临时股东会会议议程 5 | | --- | | 议案一：关于修订《公司章程》的议案 8 | | 议案二：关于修订公司部分治理制度的议案 9 | | 议案三：关于变更公司 2025 年度审计机构的议案 10 | | 议案四：关于选举董事的议案 11 | | 议案五：关于选举独立董事的议案 12 | 科美诊断技术股份有限公司（688468） 2025年第一次临时股东会会议资料 2025年第一次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证会 议的顺利进行，根据《中华人民共和国公司法》（以下简称"《公 ...

Company Overview - Company stock price on August 20 was 8.76 yuan, down 0.02 yuan from the previous trading day, a decrease of 0.23% [1] - The trading volume on that day was 71,122 hands, with a transaction amount of 0.62 billion yuan [1] - Company operates in the medical device industry, focusing on the research, production, and sales of clinical immunochemistry luminescent diagnostic testing products [1] Product and Service Range - Company’s products cover multiple testing areas including infectious diseases, tumor markers, thyroid function, and sex hormones [1] Financial Performance - In the first quarter of 2025, the company achieved operating revenue of 81.3 million yuan and a net profit of 14.54 million yuan [1] Corporate Governance - On August 20, the company announced that the board of directors has approved a proposal for a board re-election, nominating 6 non-independent director candidates and 3 independent director candidates [1] - The company plans to change its auditing firm for the 2025 fiscal year to Rongcheng Accounting Firm [1] Capital Flow - On August 20, the net inflow of main funds was 378,700 yuan, accounting for 0.01% of the circulating market value [1] - Over the past five days, the net outflow of main funds was 48.88 million yuan, representing 1.39% of the circulating market value [1]

（文章来源：证券日报） 证券日报网讯 8月20日晚间，科美诊断发布公告称，公司于2025年8月19日召开第二届董事会第十四次 会议，审议通过了《关于公司董事会换届选举暨提名第三届董事会非独立董事候选人的议案》《关于公 司董事会换届选举暨提名第三届董事会独立董事候选人的议案》，董事会同意提名李临先生、黄正铭先 生、黄燕玲女士、周琪女士、张俊杰先生、ZhiyunWang女士为公司第三届董事会非独立董事候选人， 同意提名宣建伟先生、孟召伟先生、刘宁悦女士为公司第三届董事会独立董事候选人，其中刘宁悦女士 为会计专业人士。公司将于2025年9月5日召开股东会审议董事会换届选举事宜，其中非独立董事、独立 董事均采取累积投票制选举产生，公司第三届董事会董事任期自股东会审议通过之日起三年。 ...

证券日报网讯 8月20日晚间，科美诊断发布公告称，公司拟聘任容诚会计师事务所担任公司2025年度审 计机构，负责公司2025年度财务审计及内部控制审计工作。公司已就拟变更会计师事务所的相关情况与 信永中和沟通，信永中和对本次变更事项无异议。 （文章来源：证券日报） ...